Study of PAT in Patients With Solid Tumor Cancers

Summary

This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be controlled after one or more prior therapies including a previous PD-1/PD-L1 inhibitor

Timeline

Start

2023-05-19

Primary completion

2027-01

Completion

2027-01

Drugs

Indications